drugset
drugset / Trial / NCT05333289

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289 ↗

Phase 1/2 Completed 572 enrolled ModernaTX, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.

Timeline

Start
2022-04-06
Primary completion
2022-11-22
Completion
2022-11-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Quadrivalent influenza vaccine Vaccine — Intramuscular
Subject mRNA-1020 Messenger RNA (mRNA) — Intramuscular
Subject mRNA-1030 Messenger RNA (mRNA) — Intramuscular

Indications

influenza